Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Effects of long-term aspirin use on molecular alterations in precancerous gastric mucosa in patients with and without gastric cancer.

Michigami Y, Watari J, Ito C, Hara K, Yamasaki T, Kondo T, Kono T, Tozawa K, Tomita T, Oshima T, Fukui H, Morimoto T, Das KM, Miwa H.

Sci Rep. 2017 Oct 17;7(1):13384. doi: 10.1038/s41598-017-13842-x.

2.

Effectiveness of Helicobacter pylori eradication in the prevention of primary gastric cancer in healthy asymptomatic people: A systematic review and meta-analysis comparing risk ratio with risk difference.

Seta T, Takahashi Y, Noguchi Y, Shikata S, Sakai T, Sakai K, Yamashita Y, Nakayama T.

PLoS One. 2017 Aug 17;12(8):e0183321. doi: 10.1371/journal.pone.0183321. eCollection 2017. Review.

3.

The efficacy of Jianpi Yiqi therapy for chronic atrophic gastritis: A systematic review and meta-analysis.

Dai YK, Zhang YZ, Li DY, Ye JT, Zeng LF, Wang Q, Hu L.

PLoS One. 2017 Jul 24;12(7):e0181906. doi: 10.1371/journal.pone.0181906. eCollection 2017.

4.

Outcomes of a Randomized Controlled Trial Comparing Modified High Dose Omeprazole and Amoxicillin Triple Therapy with Standard Triple Therapy for Helicobacter Pylori Eradication

Chunlertlith K, Limpapanasit U, Mairiang P, Vannaprasaht S, Tassaneeyakul W, Sangchan A, Sawadpanich K, Suttichaimongkol T, Pongpit J, Pattarapongsin M.

Asian Pac J Cancer Prev. 2017 Apr 1;18(4):927-932.

5.

Cancer prevention from the perspective of global cancer burden patterns.

Nagai H, Kim YH.

J Thorac Dis. 2017 Mar;9(3):448-451. doi: 10.21037/jtd.2017.02.75. No abstract available.

6.

Consensus on the clinical management, screening-to-treat, and surveillance of Helicobacter pylori infection to improve gastric cancer control on a nationwide scale.

Sheu BS, Wu MS, Chiu CT, Lo JC, Wu DC, Liou JM, Wu CY, Cheng HC, Lee YC, Hsu PI, Chang CC, Chang WL, Lin JT.

Helicobacter. 2017 Jun;22(3). doi: 10.1111/hel.12368. Epub 2017 Jan 8.

7.

Fas-associated factor 1 inhibits tumor growth by suppressing Helicobacter pylori-induced activation of NF-κB signaling in human gastric carcinoma.

Liu AQ, Xie Z, Chen XN, Feng J, Chen JW, Qin FJ, Ge LY.

Oncotarget. 2017 Jan 31;8(5):7999-8009. doi: 10.18632/oncotarget.14033.

8.

Epithelial Regeneration After Gastric Ulceration Causes Prolonged Cell-Type Alterations.

Aihara E, Matthis AL, Karns RA, Engevik KA, Jiang P, Wang J, Yacyshyn BR, Montrose MH.

Cell Mol Gastroenterol Hepatol. 2016 May 17;2(5):625-647. eCollection 2016 Sep.

9.

In vitro and In vivo Anti-Helicobacter pylori Activities of Centella asiatica Leaf Extract.

Zheng HM, Choi MJ, Kim JM, Lee KW, Park YH, Lee DH.

Prev Nutr Food Sci. 2016 Sep;21(3):197-201. Epub 2016 Sep 30.

10.

Etiology and Prevention of Gastric Cancer.

Cheng XJ, Lin JC, Tu SP.

Gastrointest Tumors. 2016 Sep;3(1):25-36. Epub 2016 Feb 12. Review.

11.

Recapitulating Human Gastric Cancer Pathogenesis: Experimental Models of Gastric Cancer.

Ding L, El Zaatari M, Merchant JL.

Adv Exp Med Biol. 2016;908:441-78. doi: 10.1007/978-3-319-41388-4_22. Review.

12.

New advances in targeted gastric cancer treatment.

Lazăr DC, Tăban S, Cornianu M, Faur A, Goldiş A.

World J Gastroenterol. 2016 Aug 14;22(30):6776-99. doi: 10.3748/wjg.v22.i30.6776. Review.

13.

Serum Helicobacter pylori FliD antibody and the risk of gastric cancer.

Li H, Zhang B, Hu X, Dong Y, Fan Q, Guo F, Ren X, Zhou H, Tian W, Zhao Y.

Oncotarget. 2016 Apr 19;7(16):22397-408. doi: 10.18632/oncotarget.7981.

14.

High rate of Helicobacter pylori reinfection in Lithuanian peptic ulcer patients.

Jonaitis L, Kiudelis G, Slepavicius P, Kupcinskas L.

World J Gastrointest Pathophysiol. 2016 Feb 15;7(1):181-5. doi: 10.4291/wjgp.v7.i1.181.

15.

Mutual amplification of HNF4α and IL-1R1 composes an inflammatory circuit in Helicobacter pylori associated gastric carcinogenesis.

Ma L, Zeng J, Guo Q, Liang X, Shen L, Li S, Sun Y, Li W, Liu S, Yu H, Chen C, Jia J.

Oncotarget. 2016 Mar 8;7(10):11349-63. doi: 10.18632/oncotarget.7239.

16.

Effects of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic treatment: analysis of molecular alterations by a randomised controlled trial.

Kawanaka M, Watari J, Kamiya N, Yamasaki T, Kondo T, Toyoshima F, Ikehara H, Tomita T, Oshima T, Fukui H, Daimon T, Das KM, Miwa H.

Br J Cancer. 2016 Jan 12;114(1):21-9. doi: 10.1038/bjc.2015.418. Epub 2015 Dec 15.

18.

Glycosylation-Based Serum Biomarkers for Cancer Diagnostics and Prognostics.

Kirwan A, Utratna M, O'Dwyer ME, Joshi L, Kilcoyne M.

Biomed Res Int. 2015;2015:490531. doi: 10.1155/2015/490531. Epub 2015 Oct 5. Review.

19.

Helicobacter pylori Antibody Titer and Gastric Cancer Screening.

Kishikawa H, Kimura K, Takarabe S, Kaida S, Nishida J.

Dis Markers. 2015;2015:156719. doi: 10.1155/2015/156719. Epub 2015 Sep 30. Review.

20.

Endoscopic surveillance of gastric cancers after Helicobacter pylori eradication.

Kobayashi M, Sato Y, Terai S.

World J Gastroenterol. 2015 Oct 7;21(37):10553-62. doi: 10.3748/wjg.v21.i37.10553. Review.

Supplemental Content

Support Center